NCT00563368View on ClinicalTrials.gov

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

756

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Obesity
Interventions
DRUG

VI-0521

phentermine 15 mg and topiramate 92 mg, po once daily

DRUG

VI-0521

phentermine 7.5 mg and topiramate 46 mg, po once daily

DRUG

topiramate

topiramate 46 mg, po once daily

DRUG

topiramate

topiramate 92 mg, po once daily

DRUG

phentermine

phentermine 7.5 mg, po once daily

DRUG

phentermine

phentermine 15 mg, po once daily

DRUG

VI-0521

placebo, po once daily

Trial Locations (2)

Unknown

Research Site, Durham

Research Site, Philadelphia

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

VIVUS LLC

INDUSTRY